Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide
Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide
Multidrug resistant tuberculosis (MDR-TB) is difficult to treat and raises a great challenge
 to TB control program. That pyrazinamide can shorten the course of treatment and facilitate
 bacilli clearance has been proved recently. In 2011, WHO recommended to use pyrazinamide
 throughout the course of treatment for MDR-TB. However, pyrazinamide susceptibility testing
 has not been widely used in clinic. And the conventional testing is time-consuming and
 unreliable. In contrast, the detection of pncA and rpsA mutations with molecular methods can
 provide rapid results of pyrazinamide susceptibility. The purpose of this study is to
 evaluate the efficacy of the introduce the molecular testing of pyrazinamide susceptibility
 in optimizing the MDR-TB treatment regimen.
This is a phase 3, open labeled, prospective cohort study to evaluate the molecular testing
 of pyrazinamide susceptibility in optimizing the MDR-TB treatment regimen. Approximately 100
 participants will be given the molecular detection of pncA and rpsA mutations and divide into
 to the pyrazinamide sensitive comparator group and the pyrazinamide resistant group based on
 the susceptibility results. For the pyrazinamide sensitive group, the regimen contains six
 months of chemotherapy with pyrazinamide, amikacin, levofloxacin, plus prothionamide,
 followed by six months of pyrazinamide, levofloxacin, clarithromycin, plus prothionamide. For
 the pyrazinamide resistant group, the regimen contains six months of chemotherapy with
 isoniazid, amikacin, levofloxacin, plus prothionamide, followed by eighteen months of
 isoniazid, levofloxacin, clarithromycin, plus prothionamide.

 The participants will be followed up to 24 months after the start of the treatment. The
 primary outcome is the sputum culture conversion and the adverse events. Safety evaluations
 that will be performed are the routine lab tests, blood glucose, hearing , vital signs, ECG,
 reporting of adverse events, physical examinations and X-rays.
Inclusion Criteria:

 -  Patients who are diagnosed with active tuberculosis

 -  Patients who are smear positive and sputum culture positive for tuberculosis

 -  History of active tuberculosis less than 3 years

 -  With less than 2 times of previous antituberculous therapy

 -  The patients should be voluntarily entering the study and willing to sign up the
 consent form after full knowledge of the risks, schedule, drug features of this study.

 -  MDR-TB is defined as resistance to the following two drugs: Isoniazid and Rifampicin.

 -  Extensively drug-resistant(XDR-TB) is defined as resistance to any flouroquinolones
 and any one of the three second-line antituberculous injections (capreomycin,
 kanamycin, amikacin)

 -  The study enrolled MDR-TB subjects and excluded XDR-TB subjects. If MDR-TB subjects is
 also resistant to flouroquinolones or capreomycin( kanamycin, amikacin), the subjects
 is included in the study as pre-XDR TB patients.

 Exclusion Criteria:

 -  Known allergy or intolerance to the drugs in this study

 -  Liver damage (Hepatic encephalopathy; ascites; prothrombin time prolonged 2 seconds
 compared with normal controls; blood bilirubin 3 times greater than the upper limit of
 the normal range)

 -  Platelets <150x109 / L, WBC < 3x109 / L.

 -  Abnormal ECG (Male patients with prolonged QT interval exceeding 430ms, Female
 patients with prolonged QT interval exceeding 450ms)

 -  Serum creatinine 1.5 times higher than upper limit

 -  Fasting blood-glucose higher than 8.0 mmol/L

 -  Patients who are on medication that effect the results of the drugs in this study

 -  Karnofsky score<50% (see appendix)

 -  Women who are pregnant or breastfeeding

 -  HIV positive

 -  Participating in other clinical trials in the past three months

 -  Patients with mental illness and severe neurosis

 -  Patients who have poor compliances

 -  Any special circumstances in which the research physicians believe that is not
 suitable for this study.